'Fatty liver' drug trial data sends Peninsula biotech's stock soaring more than 100%
With more than 17 million Americans with NASH, the fatty liver disease has been a prime target for drug developers. But few have been able to show promising clinical trial results.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Biotechnology | Clinical Trials | Fatty Liver Disease (FLD) | Health Management | Liver | Liver Disease | Urology & Nephrology